WD 890
Alternative Names: WD-890Latest Information Update: 05 Nov 2024
Price :
$50 *
At a glance
- Originator Ningbo Wenda Pharma
- Class Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
Most Recent Events
- 24 Jul 2024 Ningbo Wenda Pharma announces intention to submit regulatory application for market approval (Ningbo Wenda Pharma; July 2024)
- 26 Oct 2023 Phase-I clinical trials in Psoriasis (In volunteers) in China (PO) (NCT06506591)
- 26 Oct 2023 Phase-I clinical trials in Psoriatic arthritis (In volunteers) in China (PO) (NCT06506591)